Ind Swift Laboratories Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 143.15 as of 05 May 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 16.8 on March 2021 to 27.3 on March 2025 . This represents a CAGR of 10.20% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1053 crore on March 2021 to ₹ 1885 crore on March 2025 . This represents a CAGR of 12.36% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 214.2 crore as compare to the Sep '25 revenue of ₹ 243.86 crore. This represent the decline of -12.16% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 47.4 crore as compare to the Sep '25 ebitda of ₹ 49.8 crore. This represent the decline of -4.82% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 23.19 crore over 7 quarters. This represents a CAGR of 22.02% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or SMS Pharmaceuticals Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,180 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,796 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd?

As of May 5, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹135.95. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹405.35.

How do dividend payouts of Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.